Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to ...

Countries located in sub-Saharan Africa would be most affected by all funding cuts to the international HIV response.

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish ...

Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council, discusses the importance of clearly defining the role of patient representatives on pharmacy-and-therapeutics and ...

Dan Nardi, MS, CEO of Reimagine Care, claims that on-demand cancer treatment via telehealth is the future of oncology care delivery.

Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, discusses strategies for managing costs of novel cellular and gene therapies in the oncology pipeline.

Jawad Haider Butt, MD, PhD, Glasgow Cardiovascular Research Center, University of Glasgow, Glasgow, United Kingdom.

Findings presented at the American College of Cardiology Annual Scientific Session indicate that finerenone's efficacy in ...

Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida, discusses gene therapy considerations for pediatric patients and how newborn screening can influence outcomes for ...

Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in ...

JC Scott, CEO and president of The Pharmaceutical Care Management Association, discusses the evolving role pharmacy benefit managers (PBMs) play in addressing payer, provider, and patient needs.